Most researchers looking for CJC-1295 in Allo quickly find that local retail options are nearly impossible to find. The key implication for Allo researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the framework for evaluating that quality is universal across all locations. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. The sections below cover what Allo researchers need to know about sourcing, verifying, and handling CJC-1295 for scientific research use.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Allo researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Quality CJC-1295 sourcing begins with a useful first test: does this vendor share complete COA data without being asked? Suppliers that publish proactively are demonstrating research-grade standards. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. Signs of a credible vendor beyond COA quality: established track record of at least two years, knowledgeable support capable of explaining COA data, and temperature-appropriate packaging with desiccant. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order CJC-1295 — ships to Allo
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is provided for educational purposes. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Protocol documentation — keeping clear records of compound, timing, and method — is a fundamental research principle that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
